Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,782 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cancer risks and mortality in heterozygous ATM mutation carriers.
Thompson D, Duedal S, Kirner J, McGuffog L, Last J, Reiman A, Byrd P, Taylor M, Easton DF. Thompson D, et al. Among authors: taylor m. J Natl Cancer Inst. 2005 Jun 1;97(11):813-22. doi: 10.1093/jnci/dji141. J Natl Cancer Inst. 2005. PMID: 15928302
PALB2 variant status in hematological malignancies - a potential therapeutic target?
Oldreive CE, Byrd PJ, Stewart GS, Taylor AJ, Farhat S, Skowronska A, Smith E, Raghavan M, Janic D, Dokmanovic L, Clokie S, Davies N, Kwok M, Pratt G, Paneesha S, Moss P, Stankovic T, Taylor M. Oldreive CE, et al. Among authors: taylor aj, taylor m. Leuk Lymphoma. 2019 Jul;60(7):1823-1826. doi: 10.1080/10428194.2018.1551539. Epub 2019 Jan 7. Leuk Lymphoma. 2019. PMID: 30614742 No abstract available.
ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.
Kwok M, Davies N, Agathanggelou A, Smith E, Oldreive C, Petermann E, Stewart G, Brown J, Lau A, Pratt G, Parry H, Taylor M, Moss P, Hillmen P, Stankovic T. Kwok M, et al. Among authors: taylor m. Blood. 2016 Feb 4;127(5):582-95. doi: 10.1182/blood-2015-05-644872. Epub 2015 Nov 12. Blood. 2016. PMID: 26563132 Free article.
Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy.
Brose MS, Capdevilla J, Elisei R, Bastholt L, Führer-Sakel D, Leboulleux S, Sugitani I, Taylor MH, Wang Z, Wirth LJ, Worden FP, Bernard J, Caferra P, Colzani RM, Liu S, Schlumberger M. Brose MS, et al. Among authors: taylor mh. Endocr Relat Cancer. 2024 Jun 1:ERC-23-0354. doi: 10.1530/ERC-23-0354. Online ahead of print. Endocr Relat Cancer. 2024. PMID: 38828895
9,782 results